Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Teva Wins FDA Approval For Qnasl Nasal Aerosol To Treat Allergic Rhinitis

Generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA: Quote) on Monday said the U.S. Food and Drug Administration has approved Qnasl Nasal Aerosol, a new, dry nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents who are 12 years old or above.

The approval was based on a comprehensive clinical development program that assessed the product's safety and efficacy in the treatment of seasonal allergic rhinitis and perennial allergic rhinitis in patients 12 years of age and older.

Allergic rhinitis is the most common allergic disease in the U.S. It affects more than one in five people, causing some to have symptoms year round and others to experience symptoms during specific times of the year.

The safety and efficacy of Qnasl Nasal Aerosol was demonstrated in four, Phase III trials, where patients received Qnasl 320 mcg once-daily administered as two sprays in each nostril.

Intra-nasal corticosteroids are recommended as first-line therapy for allergic rhinitis and the only available option on the market before the approval of Qnasl (beclomethasone dipropionate) were aqueous formulations.

The product is expected to be available by prescription in April. It will be the first marketed non-aqueous or dry nasal aerosol in a product category that reports annual sales of $2.5 billion.

Qnasl is delivered as a once-daily, pressurized, hydrofluoroalkane or HFA-propelled non-aqueous aerosol that is environmentally friendly and offers a built-in dose counter.

Gary Gross, practicing allergist and co-founder of the Dallas Asthma and Allergy Center, said, "There are some patients with allergic rhinitis who report dissatisfaction with the currently available therapies. The approval of QNASL offers these patients a safe and effective treatment option with a new dry mode of delivery."

Teva shares, which closed at $43.07 on Friday, are adding 2.1 percent in pre-market activity.

Register
To receive FREE breaking news email alerts for Teva Pharmaceutical Industries Limited and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.